NEW YORK (GenomeWeb) — Exact Sciences today announced that the American Cancer Society's national guidelines on colorectal cancer prevention and early detection have been updated to reflect the commercial availability of the company's Cologuard cancer screening test.

Cologuard detects cancer-associated mutations and blood biomarkers in stool samples and has been shown to identify 92 percent of colorectal cancers in average risk patients with 87 percent specificity using only a single sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.